ProPhase Labs announces BE-Smart's validation for esophageal disease diagnostics, achieving over 95% success in detecting critical biomarkers. ProPhase Labs Inc. announced the successful validation of ...
Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. Company to hold a virtual conference call ...
Projections for Pharmaloz Manufacturing: Approximately $16-17 Million in Revenue, $6-7 Million in Pre-Tax Earnings for 2025 Strategic Partnership Discussions Begin for BE-Smart Esophageal Cancer Test ...
Company Actively Pursuing Strategic Alternatives Including the Potential Sale of Nebula Genomics and DNA Complete to Unlock Immediate Cash GARDEN CITY, NY, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ProPhase ...
Prophase Labs ( (PRPH)) just unveiled an update. ProPhase Labs, Inc. announced that it has entered into a non-binding letter of intent for a proposed reverse merger with Advanced Biological ...
ProPhase Labs, Inc. (PRPH) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.30 per share a year ago. These figures ...
Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results